Siga Technologies Inc. Plans Dividend of $0.60 (NASDAQ:SIGA)

Key Points

• Siga declared a dividend of $0.60 per share, with shareholders of record on April 7 and payment scheduled for April 23 (ex-dividend date April 7).
• The stock recently opened at $4.96 with a market cap of $355.35 million and a PE of 16.00; Siga reported -$0.08 EPS on $3.79 million revenue for the quarter while analysts project about 1.04 EPS for the current year.
• Weiss Ratings upgraded Siga from "sell (d+)" to "hold (c-)" on March 12, and the consensus analyst rating is currently "Hold."

Siga Technologies Inc. (NASDAQ:SIGA - Get Free Report) declared a dividend on Thursday, March 26th. Stockholders of record on Tuesday, April 7th will be given a dividend of 0.60 per share on Thursday, April 23rd. The ex-dividend date is Tuesday, April 7th.

Siga Technologies Price Performance

Shares of SIGA stock opened at $4.96 on Friday. The stock has a market cap of $355.35 million, a PE ratio of 16.00 and a beta of 0.97. The stock has a 50-day moving average of $6.24 and a 200-day moving average of $6.97. Siga Technologies has a one year low of $4.81 and a one year high of $9.62.

Siga Technologies (NASDAQ:SIGA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 10th. The company reported ($0.08) earnings per share (EPS) for the quarter. Siga Technologies had a net margin of 24.61% and a return on equity of 11.25%. The firm had revenue of $3.79 million for the quarter. As a group, research analysts anticipate that Siga Technologies will post 1.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Siga Technologies from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, March 12th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company has an average rating of "Hold".

Siga Technologies Company Profile

Siga Technologies, Inc NASDAQ: SIGA is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company's flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.

Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.